Last reviewed · How we verify
AMG 223
AMG 223 is a human monoclonal antibody that targets PCSK9.
AMG 223 is a human monoclonal antibody that targets PCSK9. Used for Hypercholesterolemia.
At a glance
| Generic name | AMG 223 |
|---|---|
| Sponsor | Amgen Research (Munich) GmbH |
| Drug class | PCSK9 inhibitor |
| Target | PCSK9 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
By binding to PCSK9, AMG 223 inhibits the degradation of LDL receptors, leading to increased LDL receptor expression on the liver surface and reduced circulating LDL cholesterol levels.
Approved indications
- Hypercholesterolemia
Common side effects
- Injection site reactions
Key clinical trials
- Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer (PHASE2)
- Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia (PHASE2)
- A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMG 223 CI brief — competitive landscape report
- AMG 223 updates RSS · CI watch RSS
- Amgen Research (Munich) GmbH portfolio CI